'War on Cancer' success examined

Share this article:
'War on Cancer' Has Made Progress
'War on Cancer' Has Made Progress

FRIDAY, Jan. 24, 2014 (HealthDay News) -- More people are being diagnosed with and dying from cancer, but this is largely the result of declines in mortality from other causes, according to a study published online Jan. 13 in the Journal of Clinical Oncology.

Samir Soneji, Ph.D., from the Geisel School of Medicine at Dartmouth in Hanover, N.H., and colleagues utilized data from the Surveillance, Epidemiology, and End Results registries to identify annual breast, colorectal, lung, and prostate cancer mortality rates. National death certificates from 1975 to 2005 were used to assess noncancer mortality rates.

The researchers found that declining cancer mortality rates reduced the burden of mortality from leading cancers, but this progress was offset by cancer incidence increases as a result of decreasing other-cause mortality rates. For instance, the burden of lung cancer in males declined by 0.1 year of life lost between 1985 to 1989 and 2000 to 2004. Two factors contributed to this decline: decreasing lung cancer mortality rates that reduced the average burden of lung cancer mortality by 0.33 years of life lost and declining other-cause mortality rates that raised it by 0.23 years. Similar patterns were seen with other common cancers.

"By using a measure that accounts for increased cancer incidence as a result of improvements in cardiovascular disease mortality, we find that prior assessments have underestimated the impact of cancer interventions," the authors write.

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

70-Gene signature not likely to be cost-effective for breast cancer

70-Gene signature not likely to be cost-effective for ...

Findings in comparative economic analysis of patients with node-negative breast cancer showed the 70-gene signature is unlikely to be cost-effective for guiding adjuvant chemotherapy decision making.

Many clinicians feel mobile apps can improve patient outcomes

Many clinicians feel mobile apps can improve patient ...

Many physicians believe digital communication technologies, including mobile apps, can be of benefit to their patients.

Overdetection of PSA recurrence after radical prostatectomy more likely in older patients

Overdetection of PSA recurrence after radical prostatectomy more ...

For some men, prostate cancer recurrence may be overdetected, especially in those aged over 70.